Supernus Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was $1,500.7 Mil.
During the past 12 months, Supernus Pharmaceuticals's average Total Assets Growth Rate was 26.30% per year.
During the past 3 years, the average Total Assets Growth Rate was -2.70% per year.
During the past 5 years, the average Total Assets Growth Rate was -3.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 22.60% per year.
During the past 13 years, Supernus Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 184.70%. The lowest was -32.40%. And the median was 29.50%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Supernus Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Supernus Pharmaceuticals Total Assets Related Terms
Supernus Pharmaceuticals Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Supernus Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a Total Assets of $1,500.7 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Total Assets too high?
Supernus Pharmaceuticals' current Total Assets is $1,500.7 Mil. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Total Assets compare to BCRX and PBH?
Supernus Pharmaceuticals' Total Assets of $1,500.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Total Assets is $1,500.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.98, compared to a current price of $46.89 — trading 14.4% above its estimated fair value. The current Total Assets is $1,500.7 Mil. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Total Assets is $1,500.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $46.89 is trading 14.4% above its estimated GF Value™ of $40.98.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
Total Assets: $1,500.7 Mil
GF Value™: $40.98 vs. price of $46.89 (14.4% above fair value)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score
Get the complete analysis for LTS:0LB2
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
